# A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

> **NCT02906202** · PHASE3 · COMPLETED · sponsor: **Genetix Biotherapeutics Inc.** · enrollment: 24 (actual)

## Conditions studied

- Beta-Thalassemia

## Interventions

- **GENETIC:** LentiGlobin BB305 Drug Product

## Key facts

- **NCT ID:** NCT02906202
- **Lead sponsor:** Genetix Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-08
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02906202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02906202, "A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02906202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*